Mangalam Drugs and Organics Share Price

Mangalam Drugs and Organics Limited was initially incorporated as Advent Pharma Private Limited on April 18, 1972. On July 1, 1997, the Company changed the name from Advent Pharma Private Limited to Mangalam Drugs and Organics Private Limited. Thereafter, it converted the status into a Public Limited Company, changing the name to Mangalam Drugs and Organics Limited on August 10, 2001. The company was established to set up a plant for manufacture of organic and inorganic chemicals.The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates. The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra. They also have an inhouse Research and Development (RD) Base. Their products include chloroquine phosphate I.P., aluminum chloride anhydrous, and dyes and intermediaries.In April 1, 1996 three other group companies, namely Mangalam Organics Pvt Ltd, Shree Mangalam Pharma Pvt Ltd and Mangalam Rasayan Pvt Ltd were amalgamated with the company. In the year 1999, the company launched a new product namely, Nimesulide. In the year 2001, they launched two new products namely Amodiaquine Hydrochloride and Amodiaquine. In the year 20032004, the bulk drug production capacity of the Company was increased from 350 MTPA to 600 MTPA. During the 200405, the capacity is being further enhanced to 960 MTPA. During the year 200506, the company further enhanced their Bulk drug production capacity from 960 MT per annum to 1260 MT per annum.During the year 200708, the company developed and introduced new bulk drugs namely Bisoprolol Fumarate and Pantaprazole Sodium. Also, they increased the production capacity of Meta Chloro Aniline Allied Products from 250 tons to 350 tons.During the year 200910, the company in addition to Regulatory Affairs Cell established Intellectual Property Rights (IPR) cell. The regulatory affairs cell submitted 6 DMFs to WHOGeneva out of which 2 DMFs corresponding to Artemether and Lumefantrine had been approved.During the year 201718, Unit 2 of the Company received WHO Approvals for manufacturing of the Active Pharmaceutical ingredients comprising of Lumefantrine (APIMF100) Tenofovir Disoproxil Fumarate (APIMF204) Artemether (APIMF138) Emtricitabine (WHO API314) Efavirenz (WHO API 318).In late 2024, the company has expanded its antimalaria API portfolio with the introduction of Pyronaridine.

For the full year FY2025–2026, revenue reached ₹318.73 crore and profit touched at ₹6.72 crore.